First-in-Human Randomized Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector
The Journal of infectious diseases | 19 Apr 2018
LR Baden, SR Walsh, MS Seaman, YZ Cohen, JA Johnson, JH Licona, RD Filter, JA Kleinjan, JA Gothing, J Jennings, L Peter, J Nkolola, P Abbink, EN Borducchi, M Kirilova, KE Stephenson, P Pegu, MA Eller, HV Trinh, M Rao, JA Ake, M Sarnecki, S Nijs, K Callewaert, H Schuitemaker, J Hendriks, MG Pau, F Tomaka, BT Korber, G Alter, R Dolin, PL Earl, B Moss, NL Michael, ML Robb and DH Barouch
Mosaic immunogens are bioinformatically engineered HIV-1 sequences designed to elicit clade independent coverage against globally circulating HIV-1 strains.
* Data courtesy of Altmetric.com